TITLE

Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies

AUTHOR(S)
Praditpornsilpa, Kearkiat; Tiranathanagul, Khajohn; Kupatawintu, Pawinee; Jootar, Saengsuree; Intragumtornchai, Tanin; Tungsanga, Kriang; Teerapornlertratt, Tanyarat; Lumlertkul, Dusit; Townamchai, Natavudh; Susantitaphong, Paweena; Katavetin, Pisut; Kanjanabuch, Talerngsak; Avihingsanon, Yingyos; Eiam-Ong, Somchai
PUB. DATE
July 2011
SOURCE
Kidney International;Jul2011, Vol. 80 Issue 1, p88
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Recombinant human erythropoietin (r-HuEpo) has been used for the treatment of renal anemia. With the loss of its patent protection, there has been an upsurge of more affordable biosimilar agents, increasing patient access to treatment for these conditions. The complexity of the manufacturing process for these recombinant proteins, however, can result in altered properties that may significantly affect patient safety. As it is not known whether various r-HuEpo products can be safely interchanged, we studied 30 patients with chronic kidney disease treated by subcutaneous injection with biosimilar r-HuEpo and who developed a sudden loss of efficacy. Sera from 23 of these patients were positive for r-HuEpo-neutralizing antibodies, and their bone marrow biopsies indicated pure red-cell aplasia, indicating the loss of erythroblasts. Sera and bone marrow biopsies from the remaining seven patients were negative for anti-r-HuEpo antibodies and red-cell aplasia, respectively. The cause for r-HuEpo hyporesponsiveness was occult gastrointestinal bleeding. Thus, subcutaneous injection of biosimilar r-HuEpo can cause adverse immunological effects. A large, long-term, pharmacovigilance study is necessary to monitor and ensure patient safety for these agents.
ACCESSION #
61249144

 

Related Articles

  • Pancytopenia Due to Massive Bone Marrow Involvement in a Patient With Primary Hyperoxaluria. Mete, Ozgur; Dogan, Oner // International Journal of Surgical Pathology;Jun2010, Vol. 18 Issue 3, p213 

    The article presents a case study of a young woman with pancytopenia. The woman had been suffering from chronic renal failure for eight years, which was due to primary hyperoxaluria. She will be treated by combined liver and kidney transplantation with bone marrow transplantation. The article...

  • Anemia.  // Mayo Clinic Health Letter;Oct2007, Vol. 25 Issue 10, p6 

    The article provides information on anemia. This medical condition occurs when one's body produces too few healthy red blood cells, loses too many of them, or destroys them faster than they can be replaced. A common form of anemia, iron deficiency is caused by loss of blood or malabsorption...

  • Managing anemia in patients with chronic kidney disease. Chalhoub, Serge; Langston, Cathy // Veterinary Medicine;May2011, Vol. 106 Issue 5, p236 

    The article discusses the management of anemia in animal patient with chronic kidney disease (CKD) cases encountered in veterinary medicine in the U.S. It highlights the major role of kidney in metabolic and endocrine functions such as control on red blood cell production from bone marrow. It...

  • Effect of erythropoietin on hepcidin, DMT1 with IRE, and hephaestin gene expression in duodenum of rats. Wei-Na Kong; Yan-Zhong Chang; Shu-Min Wang; Xing-Li Zhai; Jian-Xiu Shang; Long-xia Li; Xiang-Lin Duan // Journal of Gastroenterology;2008, Vol. 43 Issue 2, p136 

    Erythropoietin (Epo) is the central regulator of red blood cell production and can stimulate proliferation and differentiation of erythroid progenitor cells. Now, recombinant human erythropoietin (rHuEpo) is widely used in patients with renal disease, chronic anemia, and iron deficiency of early...

  • Darbepoetin Alfa: Its Use in Anemia Associated with Chronic Kidney Disease. Robinson, Dean M.; Easthope, Stephanie E. // BioDrugs;2005, Vol. 19 Issue 5, p327 

    Darbepoetin alfa (Aranesp®, Nespo®) is an amino acid substituted analog of human erythropoietin (EPO) that promotes erythrocyte survival, proliferation, and differentiation. Approved in Europe and the US for the treatment of anemia associated with chronic kidney disease (CKD), it is...

  • Modeling red blood cell survival data. Korell, Julia; Vos, Frederiek; Coulter, Carolyn; Schollum, John; Walker, Robert; Duffull, Stephen // Journal of Pharmacokinetics & Pharmacodynamics;Dec2011, Vol. 38 Issue 6, p787 

    Anaemia of chronic kidney disease (CKD) is a common complication in patients with renal impairment, especially in end-stage renal failure. As well as erythropoietin deficiency, decreased red blood cell survival is a contributing factor. However, it remains unclear which mechanism underlies the...

  • Rituximab: A viable treatment option for epoetin-induced pure red cell aplasia. Mahajan, S. A.; Nandagopal, N.; Soni, M.; Annigeri, R. A. // Indian Journal of Nephrology;Nov/Dec2015, Vol. 25 Issue 6, p366 

    Pure red cell aplasia (PRCA) due to neutralizing antibodies can rarely develop following treatment with epoetin. The treatment of this condition is generally unsatisfactory and immunosuppression is often recommended, which improves chances of hematological recovery. We describe a case of PRCAdue...

  • Is the anemia of CKD always due to erythropoietin deficiency? Garcia, Jennifer L. // Veterinary Medicine;Aug2011, Vol. 106 Issue 8, p384 

    The article provides an answer to a question on the cause of the anemia of chronic kidney disease (CKD) due to erythropoietin deficiency.

  • EPO deficit a relative deficiency.  // New Zealand Doctor;3/12/2008, p22 

    The article suggests a treatment regimen for renal anemia. Renal anemia refers to a normocytic, normochromic anemia caused by insufficient production of erythrocytes. Several factors contributing to the disease include erythropoietin (EPO) deficiency, iron deficiency, blood loss and hemolysis....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics